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MSCs inhibit antigen-induced T lymphocyte proliferation but not IFN-γ 
release. (A) CFSE-labeled splenocytes derived from mice transferred 
with HA-specific CD8+ (CL4) T cells and primed with HA-encoding 
vaccinia virus were stimulated with the HA peptide in the absence 
(No CD11b) or in the presence of CD11b+ cells magnetically purified 
from either the spleen or the tumor infiltrate of tumor-bearing mice and 
admixed at a 1:10 ratio. The cultures were stimulated for 60 hours with 
the relevant peptide, and the clonotypic proliferation was evaluated as 
CFSE dilution by flow cytometry. (B) Data are presented as the mean 
percentage of CL4 cells in each cycle from triplicate wells (± SEM); 1 
of 2 representative experiments is reported. (C) MSCs do not suppress 
IFN-γ production from naive or antigen-experienced (memory) CD8+ T 
cells. MSCs were isolated from the spleens of normal or tumor-bear-
ing mice, and 6 × 105 cells were admixed with 3 × 106 splenocytes 
containing naive (2.4 × 105) or in vivo antigen-experienced (2.1 × 105) 
HA-specific CD8+ T cells stimulated with the relevant peptide in an 
ELISPOT assay. Data (mean ± SEM) are derived from triplicate wells 
of 1 representative experiment.
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Transcripts upregulated in CD11b+ splenocytes sorted from the spleens of tumor-bearing miceA
Gene name Gene symbol Accession numberB Fold change 
Freshly isolated CD11b+ splenocytes    
Inflammatory-granulocyte response   
Regenerating islet–derived 3α Reg3a 19694 147.70
Regenerating islet–derived 2 Reg2 19693 141.25
Amylase 1, salivary Amy1 11722 124.54
Ribonuclease, RNase A family, 1 (pancreatic) Rnase1 19752 100.93
Pancreatitis-associated protein Pap 18489 73.81
Amylase 2, pancreatic Amy2 11723 72.65
Regenerating islet–derived 3γ Reg3g 19695 47.64
Pancreatic lipase-related protein 1 Pnliprp1 18946 40.48
Protease, serine, 2 Prss2 22072 39.62
Trypsin 4 Try4 22074 23.74
Kallikrein 5 Klk5 16622 19.91
Myeloperoxidase Mpo 17523 19.81
Regenerating islet–derived 1 Reg1 19692 19.71
Chymotrypsinogen B1 Ctrb1 66473 16.28
Chymotrypsin-like Ctrl 109660 14.3
Colipase, pancreatic Clps 109791 14.04
Kallikrein 6 Klk6 16612 12.13
Chemokine (C-X-C motif) ligand 1 Cxcl1 14825 11.29
Eosinophil-associated, ribonuclease A family, member 2 Ear2 13587 7.84
TNF receptor–associated factor 1 Traf1 22029 7.81
Proteinase 3 Prtn3 19152 6.7
Fas (TNF receptor superfamily member) Fas 14102 6.56
Kallikrein 22 Klk22 13646 6.25
Kallikrein 1 Klk1 16623 6.10
Eosinophil-associated, ribonuclease A family, member 1 Ear1 13586 5.23
Formyl peptide receptor 1 Fpr1 14293 4.12
Chemokine (C-X-C motif) ligand 2 Cxcl2 20310 3.78
Colony-stimulating factor 3 (granulocyte) Csf3 12985 3.5
Chemokine (C-X-C motif) ligand 3 Ccl3 20302 3.15
Matrix metalloproteinase 8 Mmp8 17394 2.62
Elastase 2 Ela2 13706 2.46
Alternative macrophage activation signature
IL-1 receptor, type II Il1r2 16178 12.17
IL-10 Il10 16153 6.66
Mannose receptor, C type 1 Mrc1 17533 6.66
IL-1α Il1a 16175 5.01
Chitinase 3–like 3 Chi3l3 12655 4.57
IL-6 Il6 16193 3.63
TGF-β–induced transcript 4 Tgfb1i4 21807 3.37
Adenosine A2b receptor  Adora2b 11541 3.26
Complement component 4 C4 12268 2.96
CD11b+ splenocytes cultured for 24 hours
IL-4/IL-13 signature    
Arginase 1, liver Arg 11846 142.18
IL-4–induced 1 Il4il 14204 26.24
Matrix metalloproteinase 12 Mmp12 17381 9.01
Annexin A4 Anxa4 11746 3.43
Serum/glucocorticoid–regulated kinase  Sgk 20393 3.55
Lectin, galactoside-binding, soluble, 3–binding protein  Lgals3bp 19039 4.29
IFN signature
IL-12a Il12a 16159 29.65
Signal transducer and activator of transcription 1 Stat1 20846 13.75
IFN regulatory factor 7 Irf7 54123 7.41
IFN-activated gene 202B Ifi202b 26388 6.3
Histocompatibility 2, T region locus 10  H2-T10 15024 5.77
IFN regulatory factor 1 Irf1 16362 5.74
Transporter 1, ATP-binding cassette, subfamily B (MDR/TAP) Tap1 21354 5
Proteasome (prosome, macropain) 28 subunit, α Psme1 19186 4.17
IFN (α and β) receptor 2 Ifnar2 15976 3.78
NO synthase 2, inducible, macrophage Nos2 18126 3.67
ATP-binding cassette, subfamily A (ABC1), member 1 Abca1 11303 3.34
Histocompatibility 2, D region locus 1 H2-D1 14964 3.02
Proteasome subunit, β type 5 Psmb5 19173 2.69
Proteasome subunit, α 1 Psma1 26440 2.28
AThe average fold changes were obtained by comparison of freshly isolated and 24-hour-cultured CD11b+ splenocytes 
from tumor-bearing mice with control CD11b+ splenocytes from tumor-free mice. BLocusLink accession number.
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CD11b+ splenocytes from tumor-bearing mice produce IFN-γ and IL-






























CD11b+ splenocytes from tumor-bearing mice produce both IFN-γ and IL-13. CD11b+ cells isolated from the 
spleens of normal BALB/c and different tumor-bearing mice (WT BALB/c, IFN-γ–/–, CD1–/–, and RAG–/–γc–/– 
KO mice) were analyzed by flow cytometry for intracellular presence of IL-13 (top panels) and IFN-γ (bot-
tom panels). Open histograms indicate staining with IL-13 or IFN-γ antibody; filled histograms indicate 
staining with isotype-matched antibody controls. Data are representative of at least 3 determinations in 
separate experiments. MFI, mean fluorescence intensity (a log scale of 100–104 was used).
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CD11b+IL-4Rα+ cells constitute a subset of inflammatory monocytes 
able to produce IL-13 and IFN-γ. Having identified IL-4Rα as a pos-
sible MSC marker, we separated tumor-induced CD11b+ spleno-
Figure 3
Evaluation of cytokines and cytokine receptors required by tumor-induced 
CD11b+ cells to inhibit generation of alloreactive and tumor-specific 
CTLs. CD11b+ sorted cells from tumor-bearing WT or different KO mice 
were added at a final concentration of 3% to a mixed leukocyte culture 
set up with BALB/c effectors stimulated with an equal number of C57BL/6 
splenocytes. After 5 days, cytotoxic activity was tested in a 5-hour 
51Cr-release assay against either a syngeneic control target (CT26, H-2d) 
or an allogeneic target (MBL-2, H-2b). Effector lymphocytes were taken 
from WT (A), IFN-γ KO (B), or IL-4 KO (C) mice. LU30, defined as the 
number of lymphocytes necessary to achieve 30% specific lysis of 
2 × 103 target cells in a 5-hour assay, was calculated on the basis of 
the total number of viable cells recovered from the cultures. Data are 
expressed as the ratio between the LU30 measured in cultures contain-
ing the third-party cells and in control cultures set up in the absence of 
third-party cells. Data are mean ± SEM from 3 experiments.
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Morphological and functional characterization of tumor-induced CD11b+IL-4Rα+ and CD11b+IL-4Rα– cells. Splenocytes were sorted by micro-
beads to select CD11b+ cells, and this cellular population was subsequently sorted by flow cytometry to select IL-4Rα+ (left panels) and IL-4Rα– 
(right panels) cells. (A) The sorted cells were stained with H&E and May-Grünwald-Giemsa stain (M-GG). Pictures were taken under microscopy 
at ×40 magnification. CD11b+IL-4Rα+ cells showed a monocytic morphology, while CD11b+IL-4Rα– cells comprised granulocytes at various dif-
ferentiation stages, including immature cells with band morphology. (B) Both populations were analyzed by flow cytometry for their expression of 
IL-13 (top panels) and IFN-γ (bottom panels). Open histograms indicate staining with IL-13 or IFN-γ antibody; filled histograms indicate isotype-
matched antibody control. Data are representative of at least 3 determinations in separate experiments. (C) The 2 populations were added at a 
final concentration of 3% to alloantigen-stimulated cultures (see above). CD11b+IL-4Rα+ but not CD11b+IL-4Rα– cells suppressed the generation 
of alloreactive CTLs (P < 0.01 and P = 0.48, respectively). Results are shown as the fraction of LU30 measured in the control allo-cultures lacking 
third-party CD11b+ cells. Data are mean ± SEM from 3 experiments.
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IL-4Rα expression is required for the in vivo inhibitory activity of myeloid 






Phenotypic characterization of 
tumor-induced CD11b+IL-4Rα+ 
cells. (A) CD11b+ cells from 
spleens of mice inoculated 9 days 
earlier with C26-GM tumor cell lines 
were enriched through immuno-
magnetic microbeads and stained 
with the indicated antibody. FS, 
forward scatter; SS, side scat-
ter. (B) Blood cells (top rows) and 
spleen cells (bottom rows) from 
mice of various strains inoculated 
with different tumors were stained 
for CD11b and IL-4Rα. The follow-
ing tumor cell lines were used: the 
BALB/c-derived colon carcinoma 
CT26 (closely related to the C26 
tumor used in our previous experi-
ments) and mammary carcinoma 
4T1; and the C57BL/6–derived 
EL-4 lymphoma and MCA203 fibro-
sarcoma. Data are from a single 
experiment representative of 3. (C) 
CD11b+ cells were sorted from the 
spleens of tumor-bearing WT or KO 
BALB/c mice and added at a final 
concentration of 3% to a mixed leu-
kocyte culture set up as previously 
described (top panels). CD11b+ 
cells sorted from the spleens of 
tumor-bearing C57BL/6 mice were 
added at a final concentration of 3% 
to a mixed leukocyte culture set up 
with C57BL/6 effectors stimulated 
with an equal number of γ-irradi-
ated BALB/c splenocytes, in the 
presence or absence of anti–IFN-γ 
and/or anti–IL-13 mAbs added at 
the beginning and at the third day of 
culture (bottom panels).
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T cells  circulating  in  the blood 
of LysMCreIL-4R–/flox tumor-bear-























ity  of  adoptive  immunotherapy 
could be obtained in the complete 
absence of IFN-γ, since the IFN-γ–/– 
mice  receiving  IFN-γ–/–  CD8+  T 
cells were completely  cured and 




by  transfer  of WT CD8+ T  cells 






IL-13 and IFN-γ collaborate to activate the suppressive metabolic path-














Adoptive cell transfer is effective only in mice with a myeloid-restricted inactivation of IL-4Rα. (A) 
LysMCreIL-4R–/flox mice and control littermates were challenged s.c. on day 0 with C26-GM cells and were 
given, 24 hours later, CD8+ T cells purified from the spleens and lymph nodes of mice vaccinated 14 days 
before with γ-irradiated C26-GM cells. Tumor size is indicated as the product of the 2 main perpendicular 
diameters measured with a caliper. Mice with tumors had to be euthanized on day 12, since they were 
showing severe signs of distress. (B) The CD3+CD8+ cells positive for the Ld tetramer loaded with AH1 
peptide were determined in the blood of tumor-bearing mice 8 days after tumor inoculation. One dot plot 
for each group is reported. Numbers indicate the percentages of AH1-TET+ cells among gated CD3+CD8+ 
T lymphocytes (mean ± SEM, n = 5–6). (C) The absolute numbers of CD3+CD8+AH1-TET+ cells were 
calculated for the total number of circulating white blood cells (WBCs) and reported as mean ± SEM. 
The background staining given by control β-gal876–884/Ld TET was subtracted for each determination. (D) 
IFN-γ–/– and WT BALB/c mice were challenged s.c. on day 0 with C26-GM cells and given, 24 hours later, 
CD8+ T cells purified from the spleens and lymph nodes of IFN-γ–/– and WT BALB/c mice, vaccinated 14 
days before with γ-irradiated C26-GM cells. Results, expressed as survival rates after tumor challenge, 
are from 1 representative experiment with 6 mice per group.
research article




































IFN-γ and IL-13 cooperate in the activation of immunosuppressive pathways. (A) Kinetics of IL-4Rα expression at the cell surface of tumor-
induced CD11b+ splenocytes. CD11b+ splenocytes from tumor-free (normal) or tumor-bearing mice (tumor) were incubated for 72 hours alone, 
with IFN-γ, with a neutralizing antibody against mouse IL-13, or with both. Isotype-matched antibodies were included as negative controls. IL-4Rα 
protein expression on the cell surface was analyzed at various time points by flow cytofluorimetry and reported as the mean percentage of 
positive cells ± SEM of 3 separate determinations. Differences between diverging kinetics values were statistically significant (P < 0.05). (B–D) 
Effect of CD11b+ cell exposure to IL-13 and IFN-γ. CD11b+ cells were sorted from the spleens of tumor-free and tumor-bearing mice. These 
last cells were analyzed immediately (Fresh) or cultured for 48 hours in medium alone (No cytokine) or in the presence of IFN-γ, IL-13, or both. 
Some samples were treated either with IFN-γ for 24 hours followed by addition of IL-13 for a further 24 hours (IFN-γ → IL-13) or with the inverse 
cytokine combination (IL-13 → IFN-γ). Cells were then analyzed for expression of Arg1 and Nos2 mRNA by real-time PCR (B), for Arg1 and 
Nos2 protein levels by Western blotting (C), and for relative enzyme activity (D). Log2FC is the log-transformed gene expression value of the 
target gene, normalized to an endogenous reference and relative to a calibrator sample. ND, not done. Data for real-time-PCR, Western blot, 
and enzyme activity are from the same experiment representative of 3.
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Phenotypic and functional characterization of CD11b+ cells infiltrating the 
tumor. (A) CD11b+ cells were separated from the disaggregated nodules 
of C26-GM tumor and stained with the indicated mAbs. (B) ARG1 and 
NOS2 protein expression level in CD11b+ cells isolated from tumors of 
WT, IL-4Rα–/–, and IFN-γ–/– BALB/c mice, analyzed immediately (Fresh) 
and after 24 hours of culture in standard medium. (C) Cytotoxicity of WT 
and IFN-γ–/– BALB/c splenocytes (Responder), stimulated with an equal 
number of γ-irradiated C57BL/6 splenocytes and cocultured without 
(None) or with CD11b+ cells sorted from tumors of WT, IL-4Rα–/–, and 
IFN-γ–/– BALB/c mice. Data are the mean of 2 separate experiments.
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Mechanisms of MSC-dependent suppression. In the “triggering 
phase,” T lymphocytes activated by exposure to the antigen release 
IFN-γ that, possibly in conjunction with a not yet identified membrane 
signal, activates inflammatory monocyte precursors. Whereas in rest-
ing condition this would result in induction of classically activated 
macrophages, monocytes conditioned by tumors show a different pro-
gram because of the expression of IL-4Rα and the ability to release 
both IL-13 and IFN-γ. The IFN-γ production, initially sustained by 
activated T lymphocytes, is subsequently amplified by the cytokine 
released from activated monocytes. IFN-γ allows the prolonged expres-
sion and signaling of IL-4Rα after engagement by IL-13 released via 
an autocrine circuit. During the “amplification phase,” the cytokines are 
thus able to maintain a prolonged activation of the enzymes NOS and 
ARG, which ultimately originate the immunosuppressive mediators act-
ing on the CD8+ T cells. This model supports the view that a prolonged 
stimulation of MSCs is necessary to mediate a full inhibition of CD8+ T 
cells and explains why T cells can initially proliferate in the presence 
of spleen-derived MSCs. On the other hand, ARG and NOS are con-
stitutively activated in tumor-infiltrating MSCs, which account for the 
prompt immunosuppression provided by these cells (Figure 1).
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approved by  the  institutional  review board of  Istituto Oncologico 
Veneto. Mice were inoculated s.c. on the left flank with tumor cells, and 
tumor growth was monitored every 2 days by caliper measurement.
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